J Hepatology: 肝功能衰竭患者的肝移植与劳力性中暑有关

2019-02-17 不详 MedSci原创

严重急性肝损伤是劳力性中暑的严重并发症。肝移植(LT)是一种治疗选择,但LT的标准和LT的最佳时机尚未明确确定。因此本研究的目的是探明劳力性中暑引发的肝损伤与肝移植之间的关系。

背景与目的
严重急性肝损伤是劳力性中暑的严重并发症。肝移植(LT)是一种治疗选择,但LT的标准和LT的最佳时机尚未明确确定。因此本研究的目的是探明劳力性中暑引发的肝损伤与肝移植之间的关系。

方法
本项研究是一项多中心,回顾性研究,研究人员对入院时诊断为劳力性中暑相关严重急性肝损伤且凝血酶原时间(PT)小于50%的患者进行了回顾性研究。本项研究共研究了24名男性患者。

结果
24名患者中有15名患者在药物治疗下病情有所改善并存活。24个中有9个被评为需紧急LT。由于PT值升高主要发生在第2天和第3天之间,最终,4名患者接受了移植,因为他们的PT持续<10%且处于劳力性中暑发作后3天,在这4名患者中,3名患者在1年后仍然存活。

结论
本项研究表明劳力性中暑相关的严重急性肝损伤的一线治疗是药物治疗。LT只是一种罕见的替代方案,不应过于草率地做出这样的决定。持续性PT <10%,在中暑发作后3天的中位时间后没有任何升高迹象,是促使LT的触发因素。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944880, encodeId=8c5c194488064, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Aug 03 03:17:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366715, encodeId=18f51366e1551, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Feb 19 10:17:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427297, encodeId=2d17142e297e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Feb 19 10:17:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944880, encodeId=8c5c194488064, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Aug 03 03:17:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366715, encodeId=18f51366e1551, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Feb 19 10:17:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427297, encodeId=2d17142e297e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Feb 19 10:17:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944880, encodeId=8c5c194488064, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Aug 03 03:17:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366715, encodeId=18f51366e1551, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Feb 19 10:17:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427297, encodeId=2d17142e297e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Feb 19 10:17:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
    2019-02-19 gwc384